The trial met its primary objectives, showing the pill’s effectiveness in helping patients with Type 2 diabetes achieve improved blood sugar control and weight loss.

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat obesity and diabetes.

Over the last couple of years, one of the best pharma stocks to own has been Eli Lilly ( LLY 14.56%). But now, an investment in Lilly may not look so enticing as the possibility of more tariffs loom. Let's explore how tariffs would impact Eli Lilly's business, and assess whether investors should buy the stock now or run for the hills instead.